On the afternoon of March 17, 2025, Nanjing Tianyinshan Hospital welcomed the launch of two clinical trial projects, bringing hope to thyroid cancer and melanoma patients. The meeting was co-chaired by Professor Qin Shukui, an internationally and domestically renowned oncology clinical research expert, and Director Chen Yingxia, Director of the Institutional Office.

On March 17, 2025, the kick-off meeting of two Phase II clinical trial projects of Scitech Pharma was held at Nanjing Tianyinshan Hospital affiliated with China Pharmaceutical University.

On December 10, 2024, the signing ceremony of the strategic cooperation agreement was held in Beijing between Beijing Scitech-MQ Pharmaceuticals Limited (Scitech Pharma) and Zhejiang Jiuzhou Pharmaceutical Limited (Jiuzhou Pharma).

Beijing Scitech-MQ Pharmaceuticals Limited (hereinafter referred to as "Scitech Pharma"), a leading Artificial Intelligence (AI)-driven drug discovery company, announced it has raised over RMB100 million in a Series A+ financing round.

On November 14, 2023, the registered clinical trial project “Multicenter, randomized, double-blind, placebo-controlled Phase II/III clinical trial to evaluate the efficacy and safety of ST-1898 tablets for the treatment of locally advanced or metastatic radioiodine-refractory differentiated thyroid cancer that has failed at least one line of TKI therapy” was successfully initiated at the Peking Union Medical College Hospital (PUMC).

On October 17, 2023, the clinical trial program of "Phase Ib/II Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of ST-1898 Tablets in Patients with Non-surgically Resectable or Metastatic Melanoma" was successfully initiated at Beijing Cancer Hospital.

On March 14, 2023, Scitech Pharma announced that ST-1898 Tablets, the first AI discovered and designed anti-tumor targeted drug, completed dosing of the first subject in Phase Ib/II clinical trial at Beijing Cancer Hospital.

On February 13, 2023, the Phase I/IIa clinical trial of ST-1703 tablets in patients with HER2-positive advanced solid tumors (including brain metastases) was successfully initiated at Jiangsu Province Hospital.